Research Topics
| Koen K Van RompaySummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategiesKoen K A Van Rompay
California National Primate Research Center, University of California, Davis, 95616, USA
AIDS Res Hum Retroviruses 28:16-35. 2012....- Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previouslyJennifer L Greenier
California National Primate Research Center, University of California, Davis, CA 95616, USA
Virol J 2:11. 2005..J. Virology 77:179-190, 2003). Here we evaluate the impact of these vaccines on oral transmission and evolution of SIV envelope variants... - Motor-biking through rural India on an HIV missionKoen K A Van Rompay
University of California, Davis, USA
AIDS 18:N13-6. 2004 - 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaquesK K Van Rompay
California Regional Primate Research Center, University of California, Davis 95616, USA
Antimicrob Agents Chemother 40:2586-91. 1996..Our data suggest that PMPA holds much promise for the treatment of human immunodeficiency virus-infected human infants and adults... - Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaquesKoen K A Van Rompay
California National Primate Research Center, University of California, Davis, CA 95616, USA
Antimicrob Agents Chemother 49:2093-4. 2005..Peak concentrations and area under the curve values of tenofovir in milk were approximately 3 and approximately 20% of those detected in serum, respectively... - Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experimentsKoen K A Van Rompay
California National Primate Research Center, University of California, Davis, CA 95616, USA
AIDS Rev 7:67-83. 2005..Accordingly, well-designed drug studies in nonhuman primates can continue to provide a solid scientific basis to advance our scientific knowledge and to guide future clinical trials... - Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11Koen K A Van Rompay
California National Primate Research Center, University of California, Davis, California, USA
Virol J 3:22. 2006..Thus, CD8+ cell-mediated immune responses play an important role in controlling SIVmac1A11 replication during acute viremia... - Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaquesKoen K A Van Rompay
California National Primate Research Center, University of California, Davis, CA 95616, USA
J Virol 80:6399-410. 2006.... - Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virusKoen K A Van Rompay
California National Primate Research Center, University of California, Davis, CA 95616 8542, USA
J Acquir Immune Defic Syndr 43:6-14. 2006..These prophylactic results further underscore the relevance of the current tenofovir DF prevention trials in pediatric and adult populations... - Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infectionKoen K A Van Rompay
California National Primate Research Center, University of California, Davis, USA
Retrovirology 4:25. 2007..Accordingly, to model HIV-1 RT responses, 12 macaques were inoculated with RT-SHIV, a chimeric SIV containing HIV-1 RT, and started on prolonged tenofovir therapy 5 months later... - Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effectsKoen K A Van Rompay
California National Primate Research Center, University of California, Davis, California 95616, USA
Antimicrob Agents Chemother 52:3144-60. 2008..In conclusion, these findings illustrate the safety and sustained benefits of prolonged TFV-containing regimens throughout development from infancy to adulthood, including pregnancy... - Evaluation of antiretrovirals in animal models of HIV infectionKoen K A Van Rompay
California National Primate Research Center, University of California, Davis, CA 95616, USA
Antiviral Res 85:159-75. 2010..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010... - Tenofovir primes rhesus macaque cells in vitro for enhanced interleukin-12 secretionKoen K A Van Rompay
California National Primate Research Center, University of California, Davis, CA 95616, USA
Antiviral Res 63:133-8. 2004.... - The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parametersKoen K A Van Rompay
The California National Primate Research Center, Davis, 95616, USA
J Acquir Immune Defic Syndr 36:900-14. 2004..Thus, the clinical benefits of tenofovir were larger than predicted by plasma viral RNA levels and other routine laboratory parameters... - CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatmentKoen K A Van Rompay
California National Primate Research Center, University of California Davis, Davis, CA 95616, USA
J Virol 78:5324-37. 2004.... - Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesKoen K A Van Rompay
California National Primate Research Center, University of California, Davis, California 95616, USA
Antimicrob Agents Chemother 48:1469-87. 2004.... - Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaquesK K Van Rompay
California Regional Primate Research Center, University of California, Davis 95616, USA
AIDS Res Hum Retroviruses 14:761-73. 1998..Our data demonstrate that PMPA treatment can reduce perinatal SIV infection and suggest that similar strategies may also be effective against HIV... - 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPAK K Van Rompay
California Regional Primate Research Center, University of California, Davis 95616, USA
Antimicrob Agents Chemother 43:802-12. 1999..These results suggest that the potential emergence of HIV mutants with reduced susceptibility to PMPA in patients during prolonged PMPA therapy may not eliminate its therapeutic benefits... - Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPAK K Van Rompay
California Regional Primate Research Center, University of California, Davis, California 95616, USA
J Virol 74:1767-74. 2000.... - Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infectionK K Van Rompay
California Regional Primate Research Center, University of California, Davis, CA 95616 8542, USA
J Infect Dis 184:429-38. 2001..These data suggest that 1 or 2 doses of PMPA may protect human newborns against intrapartum HIV infection... - Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virusKoen K A Van Rompay
California National Primate Research Center, University of California, Davis, California 95616 8542, USA
J Infect Dis 186:1508-13. 2002..In a subsequent study, 2 oral inoculations of 4 juvenile macaques with a mixture of tenofovir DF and SIVmac251 induced persistent infection. Topical administration of low doses of tenofovir DF did not protect against oral SIV infection... - Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptaseKoen K A Van Rompay
California Regional Primate Research Center, University of California, Davis, California 95616, USA
J Virol 76:6083-92. 2002..These data demonstrate that the M184V mutation in SIV conferred a slightly reduced fitness but did not affect disease outcome... - Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIVKoen K A Van Rompay
California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA
J Acquir Immune Defic Syndr 38:124-34. 2005..The results of these investigations suggest that immunization of human infants with poxvirus-based HIV vaccine candidates may offer protection against early and late HIV infection through breastfeeding... - Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIVKoen K A Van Rompay
California National Primate Research Center, University of California Davis, Davis, CA 95616, United States
Vaccine 28:1481-92. 2010.... - Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudineJeffrey P Murry
Center for Comparative Medicine, University of California, Davis 95616, USA
J Virol 77:1120-30. 2003..All animals receiving this combination developed the K65R mutation. These results demonstrate that the combination of PMPA with 3TC or (-)-FTC selects for the K65R mutation and against the M184V mutation in SIV RT... - Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251Koen K A Van Rompay
California National Primate Research Center, University of California, Davis 95616, USA
J Virol 77:179-90. 2003.... - Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1Thomas W North
Center for Comparative Medicine, University of California, Davis, CA 95616, USA
J Virol 79:7349-54. 2005..These results mimic HAART of HIV-1-infected humans. The RT-SHIV/rhesus macaque model should be useful for studies of tissue reservoirs and sites of residual replication that are not possible or practical with humans... - Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responsesKristina Abel
CNPRC CCM, School of Medicine, Division of Infectious Diseases, University of California at Davis, One Shields Ave, Davis, CA 95616, USA
J Virol 80:6357-67. 2006.... - Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challengeRuth H Florese
Vaccine Branch, National Cancer Institute, Bethesda, MD 20892-5065, USA
J Immunol 177:4028-36. 2006..Future studies should explore additional challenge routes in juvenile macaques using higher amounts of potent IgG preparations... - Long lasting control and lack of pathogenicity of the attenuated Rev-independent SIV in rhesus macaquesAgneta S von Gegerfelt
Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA
AIDS Res Hum Retroviruses 22:516-28. 2006..This study demonstrates a potent, long-lasting control of the Rev-independent attenuated SIV in macaques independent of the age at virus exposure... - Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaquesMagdalena Magierowska
Department of Medicine, University of California-San Francisco, California 94118, USA
J Virol 78:2434-44. 2004.... - Number of CD4+ and CD8+ T-cell CDR3 clonotypes expanding during acute infection of macaques with simian immunodeficiency virusFlavien Bernardin
Blood Systems Research Institute, San Francisco, CA 94118, USA
Virology 322:105-17. 2004..The lack of correlation between the number of expanding T-cell clonotypes and viremia levels may reflect the highly variable selection pressure imposed on SIV by T-cell responses targeting different epitopes in outbred macaques...
Research Grants
- Topical virucides to prevent oral transmissionKoen van Rompay; Fiscal Year: 2004..If topical tenofovir administration were effective, then this simple strategy would be highly affordable for developing countries. ..